OTS 2013 Meeting Report- Now Available

Want to learn how Oligonucleotide Therapeutics are emerging as the 3rd major drug discovery engine after small molecules and recombinant proteins?  If so, then read my report on the 9th annual meeting of the Oligonucleotide Therapeutics Society held this year from October 6-8 in Naples, Italy.  My hope is that by reading the report, corporate decision makers, investors, and scientists will learn about the key dynamics in the field to help them strategically allocate their time and capital.

Please refer to the Meeting Agenda for the presentations at the meeting.

Table of Contents                                                                                          Page

I.                    Introduction                                                                                  2

II.                  Themes and Trends                                                                     3

A.      Multiple high-impact therapeutic opportunities               3

B.      Thinking small: focus on oligonucleotide chemistry        4

C.      New antisense applications mushrooming                       5

D.     Few new oligo inducer structures and delivery                7

E.      The Duchenne muscular dystrophy phenomenon               9

III.                Highlights from the various oligonucleotide modalities              10

A.      Aptamers                                                                          10

B.      Immunomodulatory oligonucleotides                                11

C.      mRNA Therapeutics                                                         12

D.     RNAi Therapeutics                                                           13

E.      LncRNA Therapeutics                                                      17

F.       Therapeutics splice modulation                                       19

G.     MicroRNA Therapeutics                                                  22

H.     RNaseH Antisense                                                            23

Pricing 

(15% discount for those that have ordered the 2013 RNAi Therapeutics Investment Guide)

Drug development companies up to 10 employees: 250 Euros/300 US dollars

Drug development companies over 10 employees: 500 Euros/600 US dollars

Other companies (e.g. financial institutions and investment funds): 500 Euros/600 US dollars

University libraries: 125 Euros/160 dollars

Individuals (private use only): 100 Euros/130 US dollars

Prices exclude 19% VAT for German customers (corporate and non-corporate) and non-corporate customers in the European Union.

Payments either by bank transfer or paypal.

When ordering, the following information is required:

Full name and address

Billing address if different  

Use (corporate, individual etc)

Order by contacting me at myfirstname.mylastnameATgmail.com
My first name: dirk; my last name: haussecker